FINE FOODS & PHARMACEUTICALS N.T.M. S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.4 EUR | +0.48% |
|
+0.96% | -4.22% |
| 02/04 | Fine Foods narrows loss in 2023; up 22 percent in revenue | AN |
| 29/03 | Fine Foods & Pharmaceuticals N.T.M. S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 272.3 | 237.8 | 374.5 | 204.6 | 214.8 | 205.7 | - | - |
| Enterprise Value (EV) 1 | 232.5 | 184 | 390.1 | 248.2 | 258.4 | 271.6 | 291.7 | 281.7 |
| P/E ratio | 35.9 x | 19.1 x | -257 x | -22.5 x | -62.6 x | 21.9 x | 16.6 x | 11.8 x |
| Yield | 1% | 1.33% | 1.04% | 1.2% | 1.37% | 1.41% | 1.39% | 1.39% |
| Capitalization / Revenue | 1.71 x | 1.34 x | 1.92 x | 0.98 x | 0.85 x | 0.75 x | 0.69 x | 0.59 x |
| EV / Revenue | 1.46 x | 1.04 x | 2 x | 1.19 x | 1.02 x | 0.99 x | 0.98 x | 0.8 x |
| EV / EBITDA | 11.2 x | 8.26 x | 18.4 x | 15.8 x | 10 x | 8.11 x | 7.44 x | 5.82 x |
| EV / FCF | -251 x | 142 x | -1,046 x | 20.2 x | 627 x | -8.49 x | -58.3 x | 21.7 x |
| FCF Yield | -0.4% | 0.7% | -0.1% | 4.95% | 0.16% | -11.8% | -1.71% | 4.62% |
| Price to Book | 1.51 x | 1.34 x | 2.49 x | 1.6 x | 1.77 x | 1.61 x | 1.49 x | 1.35 x |
| Nbr of stocks (in thousands) | 22,693 | 22,650 | 24,315 | 24,538 | 24,495 | 24,482 | - | - |
| Reference price 2 | 12.00 | 10.50 | 15.40 | 8.340 | 8.770 | 8.400 | 8.400 | 8.400 |
| Announcement Date | 31/03/20 | 30/03/21 | 30/03/22 | 30/03/23 | 29/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 159.7 | 177 | 195.2 | 208.3 | 252.9 | 273.3 | 297 | 350 |
| EBITDA 1 | 20.79 | 22.29 | 21.17 | 15.7 | 25.83 | 33.48 | 39.2 | 48.4 |
| EBIT 1 | 9.706 | 10.65 | 7.714 | -1.011 | 9.705 | 16.01 | 21.4 | 28 |
| Operating Margin | 6.08% | 6.02% | 3.95% | -0.49% | 3.84% | 5.86% | 7.21% | 8% |
| Earnings before Tax (EBT) 1 | 7.725 | 16.68 | -4.59 | -14.2 | -1.855 | 12.36 | 16 | 24 |
| Net income 1 | 6.07 | 13.36 | -1.427 | -9.501 | -3.522 | 10 | 13 | 18 |
| Net margin | 3.8% | 7.55% | -0.73% | -4.56% | -1.39% | 3.66% | 4.38% | 5.14% |
| EPS 2 | 0.3345 | 0.5500 | -0.0600 | -0.3700 | -0.1400 | 0.3830 | 0.5070 | 0.7100 |
| Free Cash Flow 1 | -0.9252 | 1.294 | -0.3731 | 12.3 | 0.4119 | -32 | -5 | 13 |
| FCF margin | -0.58% | 0.73% | -0.19% | 5.9% | 0.16% | -11.71% | -1.68% | 3.71% |
| FCF Conversion (EBITDA) | - | 5.81% | - | 78.32% | 1.59% | - | - | 26.86% |
| FCF Conversion (Net income) | - | 9.68% | - | - | - | - | - | 72.22% |
| Dividend per Share 2 | 0.1200 | 0.1400 | 0.1600 | 0.1000 | 0.1200 | 0.1185 | 0.1170 | 0.1170 |
| Announcement Date | 31/03/20 | 30/03/21 | 30/03/22 | 30/03/23 | 29/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 S1 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 76.52 | 75.35 | 101.6 | 98.61 | 49.26 | 96.63 | - | 52.24 | 55.18 | 128.6 | 58.23 | 67.22 |
| EBITDA 1 | 8.01 | 9.8 | 12.49 | 13.14 | 2.332 | 8.03 | - | 4.2 | 3.1 | - | - | 7.507 |
| EBIT 1 | 2.46 | 3.245 | 7.405 | 6.728 | -1.479 | 0.9861 | - | 0.3508 | -1.996 | - | - | 3.137 |
| Operating Margin | 3.21% | 4.31% | 7.29% | 6.82% | -3% | 1.02% | - | 0.67% | -3.62% | - | - | 4.67% |
| Earnings before Tax (EBT) 1 | 3.232 | 4.175 | 12.51 | -4.071 | -2.415 | -0.5196 | -5.894 | -5.673 | -2.632 | - | - | -2.367 |
| Net income 1 | 2.852 | 3.117 | 10.25 | -6.467 | 1.462 | 5.04 | -6.036 | -5.853 | 2.388 | -1.663 | -0.0971 | -1.762 |
| Net margin | 3.73% | 4.14% | 10.09% | -6.56% | 2.97% | 5.22% | - | -11.21% | 4.33% | -1.29% | -0.17% | -2.62% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 31/03/20 | 29/09/20 | 30/03/21 | 13/09/21 | 30/03/22 | 30/03/22 | 13/09/22 | 14/11/22 | 30/03/23 | 13/09/23 | 14/11/23 | 29/03/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 15.7 | 43.6 | 43.6 | 66 | 86 | 76 |
| Net Cash position 1 | 39.8 | 53.8 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | 0.7405 x | 2.777 x | 1.686 x | 1.97 x | 2.194 x | 1.57 x |
| Free Cash Flow 1 | -0.93 | 1.29 | -0.37 | 12.3 | 0.41 | -32 | -5 | 13 |
| ROE (net income / shareholders' equity) | 4.08% | 6.88% | 7.07% | -6.13% | 3.79% | 7.46% | 9.3% | 12% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 7.930 | 7.830 | 6.190 | 5.210 | 4.970 | 5.230 | 5.620 | 6.210 |
| Cash Flow per Share 2 | 1.060 | 0.7000 | 0.6500 | 0.1400 | 0.7300 | 1.110 | - | - |
| Capex 1 | 19.4 | 15.8 | 15.9 | 15 | 18.1 | 53.6 | 29.9 | 27.5 |
| Capex / Sales | 12.16% | 8.93% | 8.15% | 7.21% | 7.17% | 19.61% | 10.07% | 7.86% |
| Announcement Date | 31/03/20 | 30/03/21 | 30/03/22 | 30/03/23 | 29/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.4
EUR
Average target price
12.25
EUR
Spread / Average Target
+45.83%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.22% | 220M | |
| +8.20% | 7.78B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.13% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- FF Stock
- Financials Fine Foods & Pharmaceuticals N.T.M. S.p.A.
